Now showing items 177-196 of 666

    • Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. 

      Veldhuijzen van Zanten, SEM; Baugh, J; Chaney, B; De Jongh, D; Sanchez Aliaga, E; Barkhof, F; Noltes, J; De Wolf, R; Van Dijk, J; Cannarozzo, A; Damen-Korbijn, CM; Lieverst, JA; Colditz, N; Hoffmann, M; Warmuth-Metz, M; Bison, B; Jones, DTW; Sturm, D; Gielen, GH; Jones, C; Hulleman, E; Calmon, R; Castel, D; Varlet, P; Giraud, G; Slavc, I; Van Gool, S; Jacobs, S; Jadrijevic-Cvrlje, F; Sumerauer, D; Nysom, K; Pentikainen, V; Kivivuori, S-M; Leblond, P; Entz-Werle, N; von Bueren, AO; Kattamis, A; Hargrave, DR; Hauser, P; Garami, M; Thorarinsdottir, HK; Pears, J; Gandola, L; Rutkauskiene, G; Janssens, GO; Torsvik, IK; Perek-Polnik, M; Gil-da-Costa, MJ; Zheludkova, O; Shats, L; Deak, L; Kitanovski, L; Cruz, O; Morales La Madrid, A; Holm, S; Gerber, N; Kebudi, R; Grundy, R; Lopez-Aguilar, E; Zapata-Tarres, M; Emmerik, J; Hayden, T; Bailey, S; Biassoni, V; Massimino, M; Grill, J; Vandertop, WP; Kaspers, GJL; Fouladi, M; Kramm, CM; van Vuurden, DG; members of the SIOPE DIPG Network (2017-04)
      Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in ...
    • Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. 

      Muñoz-López, A; Romero-Moya, D; Prieto, C; Ramos-Mejía, V; Agraz-Doblas, A; Varela, I; Buschbeck, M; Palau, A; Carvajal-Vergara, X; Giorgetti, A; Ford, A; Lako, M; Granada, I; Ruiz-Xivillé, N; Rodríguez-Perales, S; Torres-Ruíz, R; Stam, RW; Fuster, JL; Fraga, MF; Nakanishi, M; Cazzaniga, G; Bardini, M; Cobo, I; Bayon, GF; Fernandez, AF; Bueno, C; Menendez, P (2016-09-20)
      Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming ...
    • Diagnostic issues in chronic lymphocytic leukaemia (CLL) 

      Matutes, E; Catovsky, D (ELSEVIER SCI LTD, 2010-03)
      The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the initial diagnostic investigations. In atypical cases, these tests should be complemented ...
    • Diagnostic significance of CD20 and FMC7 expression in B-cell disorders 

      Delgado, J; Matutes, E; Morilla, AM; Morilla, RM; Owusu-Ankomah, KA; Rafiq-Mohammed, F; del Giudice, I; Catovsky, D (AMER SOC CLINICAL PATHOLOGY, 2003-11)
      We analyzed by flow cytometry the expression of CD20 and FMC7 in cell suspensions from 932 patients, including 630 cases of chronic lymphocytic leukemia (CLL), 23 cases of other B-cell leukemias, and 279 cases of B-cell ...
    • Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. 

      Ferrari, N; Ranftl, R; Chicherova, I; Slaven, ND; Moeendarbary, E; Farrugia, AJ; Lam, M; Semiannikova, M; Westergaard, MCW; Tchou, J; Magnani, L; Calvo, F (2019-01-10)
      Aggressive behaviours of solid tumours are highly influenced by the tumour microenvironment. Multiple signalling pathways can affect the normal function of stromal fibroblasts in tumours, but how these events are coordinated ...
    • Differential diagnosis in chronic lymphocytic leukaemia 

      Matutes, E (ELSEVIER SCIENCE BV, 2007-09)
      The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the key initial diagnostic tests. In cases with atypical features, these investigations ...
    • Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. 

      Labreche, K; Kinnersley, B; Berzero, G; Di Stefano, AL; Rahimian, A; Detrait, I; Marie, Y; Grenier-Boley, B; Hoang-Xuan, K; Delattre, J-Y; Idbaih, A; Houlston, RS; Sanson, M (2018-05)
      Recent genome-wide association studies of glioma have led to the discovery of single nucleotide polymorphisms (SNPs) at 25 loci influencing risk. Gliomas are heterogeneous, hence to investigate the relationship between ...
    • Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways 

      Ashworth, A (2004-06)
      Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways Fanconi anaemia (FA) is a chromosomal instability disorder characterized by cellular sensitivity to DNA interstrand crosslinking agents and a high ...
    • Directing the use of DDR kinase inhibitors in cancer treatment. 

      Brandsma, I; Fleuren, EDG; Williamson, CT; Lord, CJ (2017-12)
      INTRODUCTION: Defects in the DNA damage response (DDR) drive the development of cancer by fostering DNA mutation but also provide cancer-specific vulnerabilities that can be exploited therapeutically. The recent approval ...
    • Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. 

      Dodson, A; Okonji, D; Assersohn, L; Rigg, A; Sheri, A; Turner, N; Smith, I; Parton, M; Dowsett, M (2018-02)
      PURPOSE: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) ...
    • Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. 

      Martin, L-A; Ribas, R; Simigdala, N; Schuster, E; Pancholi, S; Tenev, T; Gellert, P; Buluwela, L; Harrod, A; Thornhill, A; Nikitorowicz-Buniak, J; Bhamra, A; Turgeon, M-O; Poulogiannis, G; Gao, Q; Martins, V; Hills, M; Garcia-Murillas, I; Fribbens, C; Patani, N; Li, Z; Sikora, MJ; Turner, N; Zwart, W; Oesterreich, S; Carroll, J; Ali, S; Dowsett, M (2017-11-30)
      Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, ...
    • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. 

      Puyang, X; Furman, C; Zheng, GZ; Wu, ZJ; Banka, D; Aithal, K; Agoulnik, S; Bolduc, DM; Buonamici, S; Caleb, B; Das, S; Eckley, S; Fekkes, P; Hao, M-H; Hart, A; Houtman, R; Irwin, S; Joshi, JJ; Karr, C; Kim, A; Kumar, N; Kumar, P; Kuznetsov, G; Lai, WG; Larsen, N; Mackenzie, C; Martin, L-A; Melchers, D; Moriarty, A; Nguyen, T-V; Norris, J; O'Shea, M; Pancholi, S; Prajapati, S; Rajagopalan, S; Reynolds, DJ; Rimkunas, V; Rioux, N; Ribas, R; Siu, A; Sivakumar, S; Subramanian, V; Thomas, M; Vaillancourt, FH; Wang, J; Wardell, S; Wick, MJ; Yao, S; Yu, L; Warmuth, M; Smith, PG; Zhu, P; Korpal, M (2018-09)
      Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant ...
    • Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer. 

      Murillo, MM; Rana, S; Spencer-Dene, B; Nye, E; Stamp, G; Downward, J (2018-12-26)
      RAS family GTPases contribute directly to the regulation of type I phosphoinositide 3-kinases (PI3Ks) via RAS-binding domains in the PI3K catalytic p110 subunits. Disruption of this domain of p110α impairs RAS-mutant-onc ...
    • Dissecting PARP inhibitor resistance with functional genomics. 

      Pettitt, SJ; Lord, CJ (2019-02)
      The poly-(ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib was the first licenced cancer drug that targeted an inherited form of cancer, namely ovarian cancers caused by germline BRCA1 or BRCA2 gene mutations. ...
    • Divergent adaptation in thyroid cancers. 

      Sottoriva, A (2018-06-01)
    • DNA methylation-based classification of central nervous system tumours. 

      Capper, D; Jones, DTW; Sill, M; Hovestadt, V; Schrimpf, D; Sturm, D; Koelsche, C; Sahm, F; Chavez, L; Reuss, DE; Kratz, A; Wefers, AK; Huang, K; Pajtler, KW; Schweizer, L; Stichel, D; Olar, A; Engel, NW; Lindenberg, K; Harter, PN; Braczynski, AK; Plate, KH; Dohmen, H; Garvalov, BK; Coras, R; Hölsken, A; Hewer, E; Bewerunge-Hudler, M; Schick, M; Fischer, R; Beschorner, R; Schittenhelm, J; Staszewski, O; Wani, K; Varlet, P; Pages, M; Temming, P; Lohmann, D; Selt, F; Witt, H; Milde, T; Witt, O; Aronica, E; Giangaspero, F; Rushing, E; Scheurlen, W; Geisenberger, C; Rodriguez, FJ; Becker, A; Preusser, M; Haberler, C; Bjerkvig, R; Cryan, J; Farrell, M; Deckert, M; Hench, J; Frank, S; Serrano, J; Kannan, K; Tsirigos, A; Brück, W; Hofer, S; Brehmer, S; Seiz-Rosenhagen, M; Hänggi, D; Hans, V; Rozsnoki, S; Hansford, JR; Kohlhof, P; Kristensen, BW; Lechner, M; Lopes, B; Mawrin, C; Ketter, R; Kulozik, A; Khatib, Z; Heppner, F; Koch, A; Jouvet, A; Keohane, C; Mühleisen, H; Mueller, W; Pohl, U; Prinz, M; Benner, A; Zapatka, M; Gottardo, NG; Driever, PH; Kramm, CM; Müller, HL; Rutkowski, S; von Hoff, K; Frühwald, MC; Gnekow, A; Fleischhack, G; Tippelt, S; Calaminus, G; Monoranu, C-M; Perry, A; Jones, C; Jacques, TS; Radlwimmer, B; Gessi, M; Pietsch, T; Schramm, J; Schackert, G; Westphal, M; Reifenberger, G; Wesseling, P; Weller, M; Collins, VP; Blümcke, I; Bendszus, M; Debus, J; Huang, A; Jabado, N; Northcott, PA; Paulus, W; Gajjar, A; Robinson, GW; Taylor, MD; Jaunmuktane, Z; Ryzhova, M; Platten, M; Unterberg, A; Wick, W; Karajannis, MA; Mittelbronn, M; Acker, T; Hartmann, C; Aldape, K; Schüller, U; Buslei, R; Lichter, P; Kool, M; Herold-Mende, C; Ellison, DW; Hasselblatt, M; Snuderl, M; Brandner, S; Korshunov, A; von Deimling, A; Pfister, SM (2018-03-22)
      Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown ...
    • DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. 

      Touat, M; Sourisseau, T; Dorvault, N; Chabanon, RM; Garrido, M; Morel, D; Krastev, DB; Bigot, L; Adam, J; Frankum, JR; Durand, S; Pontoizeau, C; Souquère, S; Kuo, M-S; Sauvaigo, S; Mardakheh, F; Sarasin, A; Olaussen, KA; Friboulet, L; Bouillaud, F; Pierron, G; Ashworth, A; Lombès, A; Lord, CJ; Soria, J-C; Postel-Vinay, S (2018-04-02)
      Synthetic lethality is an efficient mechanism-based approach to selectively target DNA repair defects. Excision repair cross-complementation group 1 (ERCC1) deficiency is frequently found in non-small-cell lung cancer ...
    • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 

      Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; Perez-Lopez, R; Nava Rodrigues, D; Robinson, D; Omlin, A; Tunariu, N; Boysen, G; Porta, N; Flohr, P; Gillman, A; Figueiredo, I; Paulding, C; Seed, G; Jain, S; Ralph, C; Protheroe, A; Hussain, S; Jones, R; Elliott, T; McGovern, U; Bianchini, D; Goodall, J; Zafeiriou, Z; Williamson, CT; Ferraldeschi, R; Riisnaes, R; Ebbs, B; Fowler, G; Roda, D; Yuan, W; Wu, YM; Cao, X; Brough, R; Pemberton, H; A'Hern, R; Swain, A; Kunju, LP; Eeles, R; Attard, G; Lord, CJ; Ashworth, A; Rubin, MA; Knudsen, KE; Feng, FY; Chinnaiyan, AM; Hall, E; de Bono, JS
      Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to ...
    • Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. 

      Natrajan, R; Tutt, ANJ; Lord, CJ (2018-03)
      <b/> Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms ...